Abstract
As more pathology laboratories are transitioning to a digital workflow, the availability of commercial Artificial Intelligence assistance systems is also increasing. Today nearly 40 such products approved for diagnostic use are available. This article provides an overview of the most widely addressed use cases, including Immunohistochemistry scoring for breast cancer and non-small-cell lung cancer, Gleason grading for prostate cancer, or metastasis detection in lymph nodes. While automation alone already promises an increase in efficiency that may help to bridge the growing gap between supply (pathology work force) and demand (histological testing), this article introduces another category of Artificial Intelligence products that go beyond just mimicking today’s established score. Various Artificial Intelligence are being introduced that detect genetic alterations or stratify risk, directly from the standard hematoxylin & eosin staining. Finally, a brief outlook explains how basic AI models are currently finding their way into computational pathology and promise to further accelerate product developments by decreasing the time-to-model.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
